Shares of Westlake Village-based MannKind were up 5% during the trading day on Nov. 8, after the company released its earnings for the third quarter of 2022, with revenue and earnings topping analysts’ expectations. MannKind, a biotechnology company that develops treatments for diabetes and pulmonary arterial hypertension, had a net loss of $14.4 million for…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
